Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Italian organ transplant supply still short of demand:

This article was originally published in Clinica

Executive Summary

Italy performed 3,216 organ transplants last year, up almost 17% annually, from 2,756, but this still falls far short of the actual need. According to the 2004 health ministry report, around 1,750 patients received a kidney, 1,020 a liver, 353 a heart, 82 a lung, 94 a pancreas and seven underwent intestinal transplant. By contrast, the numbers of patients waiting for an organ at the end of 2004 were around: 6,600 for a kidney, 1,460 for a liver, 640 for a heart, 210 for a pancreas and 250 for a lung. Italy ranks second in the EU by number of donors, at 21.1 per million inhabitants (dpm) - Spain is claiming the world leadership in transplant activity, at 34.6 dpm in 2004, up 3.5% since 2003.

You may also be interested in...

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts